《新股消息》富衛向聯交所重新提交主板上市申請
富衛集團宣布,向香港聯交所重新提交A1表格作主板上市申請。聯席保薦人為摩根士丹利、高盛、招銀國際及摩根大通。
富衛提到,其於香港及澳門、泰國及柬埔寨、日本及新興市場業務在2021年分別對集團新業務價值貢獻29.8%、31.7%、19.1%及19.4%,而於2022年分別對新業務價值貢獻26.3%、32.8%、16.8%及24.1%。集團主要產品分類為分紅人壽;非分紅人壽;危疾、定期人壽、醫療及附加保險;投資相連壽險;團體保險及企業自有人壽保險,於2022年分別對新業務價值貢獻18.9%、25.2%、34.5%、12.3%、6.9%及2.1%。
截至去年12月31日止年度,富衛錄得淨虧損7.4億美元,而2021年則錄淨利潤2.49億美元。以非國際財務報告準則計量,2022財年經調整淨虧損為8.23億美元,2021年同期則為淨利潤1.88億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.